Another anticoagulant available for thromboprophylaxis is fondaparinux, an indirect inhibitor of activated factor X. In a double-blind, non-inferiority trial of 2,927 patients undergoing high-risk ...

(HealthDay News) — For patients hospitalized for COVID-19, administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality ...

The mean time to achieve therapeutic anticoagulation was significantly less in the anti-Xa HA group compared with the aPTT group (p < 0.0001). Furthermore, a significantly greater percentage of ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

The number of patients under anticoagulation therapy is on the rise, and thereby, the demand for anticoagulants also increases. In 2022, 702,880 people died from heart disease, and such deaths ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective ...